work bevyxxa
attend esc result marin trial rivaroxaban
medic ill patient miss primari endpoint symptomat vte vte-rel
death secondari endpoint includ vte-rel death hr
event rate compar similar studi includ apex betrixaban may stem
healthier patient popul younger shorter hospit mobil
marin safeti data includ major bleed rate vs placebo
see marin result posit bevyxxa due less competit highlight
favor product profil anticip addit effort remain order gain
access drive demand rais sg lower pt
marin show signific improv primari endpoint
efficaci vte-rel death hr symptomat vte hr
see result favor betrixaban due less
competit acut medic patient see exhibit detail result
mix result marin may neg impact fxa class
extend vte prophylaxi post-discharg muddi perceiv risk-benefit
equat marin conduct less ill popul apex show
benefit sever popul see target popul vte
prophylaxi key consider treatment guidelin updat
difficult compar across marin apex especi due differ
baselin demograph betrixaban reach statist signific vs soc
combin measur non-hemorrhag cardiopulmonari death non-fat
pe mi ischem stroke fatal bleed ich hr
nnt visit day continu improv
confid andexxa increas base recent publish evid
andexxa superior bind properti vs ciraparantag
separ data present aha suggest ciraparantag revers
anticoagul activ xarelto eliqui wherea andexxa demonstr rapid
revers minut highli correl hemostat efficaci
lower pt base increas invest requir drive
post-discharg use bevyxxa vte prevent base marin discuss
may also muddi view clinician see target popul vte
prophylaxi key consider treatment guidelin get updat
expect higher sg expens support betrixaban
portola pharmaceut focus
develop commerci
novel therapeut meet patient
need thrombosi hematolog
disord oncolog
analyst certif import disclosur see disclosur
eu approv andexanet
andexanet manufactur on-line
rapid and/or greater expect uptak betrixaban
sign eu partner commerci betrixaban and/or andexanet
longer expect exclus betrixaban and/or andexanet
rapid and/or better expect develop cerdulatinib
outperform rate share base optim
three differenti asset increas confid
market potenti view betrixaban import innov
prevent vte venou thromboembol acut
medic ill patient look forward full us
launch similarli believ andexanet provid import
antidot factor xa inhibitor patient experi
episod acut bleed look forward potenti ema
approv earli also includ cerdulatinib model
end august potenti pa submiss manufactur
earli approv product full andexxa launch
potenti chmp posit opinion andexanet europ
addit data cerdulatinib cll sll fl end
meet fda
delay european approv andexanet
signific competit betrixaban and/or andexanet
failur get andexanet manufactur on-line
shorter expect exclus betrixaban and/or andexanet
outperform rate base optimist view ahead bevyxxa launch andexxa regulatori review cerdulatinib
develop price target base dcf valuat wacc residu growth rate base patent expir
potenti sourc upsid includ sign eu partner andexxa clinic progress cerdulatinib
key risk price target regulatori risk andexxa eu commerci risk bevyxxa us eventu andexxa
us eu addit risk come potenti challeng build hospital-bas sale organ and/or lower
expect peak sale due higher anticip competit failur gain support medic commun healthcar
prescrib payer
exhibit marin trial xarelto rivaroxaban medic ill patient prophylaxi vte
exhibit marin fail show signific improv primari endpoint symptomat
vte vte-rel death subgroup analysi show xarelto may yield improv
symptomat vte alon vte-rel death safeti line placebo term
statist signific major bleed
exhibit marin fail show signific improv primari endpoint symptomat
vte vte-rel death
exhibit lower dose base pk/pd model renal impair patient perform less
well compar dose normal patient
exhibit apex betrixaban vte prevent outcom
exhibit audienc question noac use vte prevent esc post marin data
exhibit pt base dcf valuat methodolog
portola dcfdiscount analysi except per-shar data mn except per-shar data revenu chang work work capit valu growth valu oppenheim co equiti valu per sharetermin valu growth rate outperform
probabl success
probabl success
probabl success
licens revenu mileston
good
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
adjust research develop non-gaap
share-bas compens
total share-bas compens
total share-bas compens exclud non-gaap op ex
total non-oper income/ expens
earn tax
adjust special item
total special item net tax
net incom continu oper
net incom attribut common sharehold basic
net incom attribut common sharehold dilut
stock price compani mention report
